Drug Trial Radar · NCT05756153
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Apr 25, 2023
Primary completion
Apr 30, 2025
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II study. The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC
Conditions
- Advance Non-small Cell Lung Cancer
Interventions
GFH925Drug
GFH925 tablets administered orally daily.
CetuximabDrug
Cetuximab administered intravenously Q2W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: adverse eventsTime frame: 28 days
- Phase II: objective response rateTime frame: up to 1 year after last patient in
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
General Hospital of Athens "Alexandra"
Athens, Greece
University General Hospital "Attikon"
Athens, Greece
Bioclinic Thessaloniki
Thessaloniki, Greece
University General Hospital "Attikon"
Athens, Haidari, Greece
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Emilia-Romagna, Italy
IRCCS Centro di Riferimento Oncologico
Aviano, Friuli Venezia Giulia, Italy
IOV - Istituto Oncologico Veneto IRCCS
Padova, Friuli Venezia Giulia, Italy
Istituto Nazionale Tumori Regina Elena IRCCS
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Candiolo Cancer Institute, FPO-IRCCS
Candiolo, Piedmont, Italy
A.O.U. Senese Policlinico Santa Maria alle Scotte
Siena, Tuscany, Italy
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
Verona, Veneto, Italy
Hospital Universitari Dexeus,Servicio de Oncologia Medica
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Clinica Mi Tres Torres
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Regional Universitario de Malaga,Oncology Dept
Málaga, Spain
Virgen del Rocio University Hospital
Seville, Spain
Instituto Valenciano de Oncologia IVO,Servicio de Oncologia Medica
Valencia, Spain
ICO Badalona - Hospital Universitari Germans Trias i Pujol,Servicio de Oncologia Medica
Badalona, Barcelona, Spain
Clinica Universidad de Navarra, Servicio de Oncologia
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.